polybiocept Revenue
Biotechnology Research • 
Alzenau in Unterfranken, Bavaria, Germany • 1-10 Employees
$
polybiocept revenue & valuation
| Annual revenue | $85,555 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $273,776 |
| Total funding | No funding |
Key Contact at polybiocept
Hendrik Jakowlew
Creative Director
Company overview
| Headquarters | Siemensstraße 24, Alzenau in Unterfranken, Bavaria 63755, DE |
| Website | |
| NAICS | 541714 |
| Keywords | Oncology, Infectious Diseases, Autoimmune Diseases |
| Founded | 2017 |
| Employees | 1-10 |
About polybiocept
Cancer is globally considered as one of the deadliest diseases. The polybiocept group and it’s founders mission is to contribute changing the dramatic impact cancer has on individuals and on societies. polybiocept is a clinical stage biotech company developing autologous cell therapies with an initial focus on the most lethal cancer indications pancreatic cancer and Glioblastoma (a brain tumor).
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Director
Funding Data
polybiocept has never raised funding before.
United Kingdom
United States
Spain
Frequently asked questions
polybiocept is located in Alzenau in Unterfranken, Bavaria, DE.
polybiocept generates an estimated annual revenue of $85,555. This revenue figure reflects the company's market position and business performance in its industry.
polybiocept has an estimated valuation of $273,776. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.
polybiocept was founded in 2017, making it 9 years old. The company has established itself as a significant player in its industry over this time.
polybiocept has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.
4.8
40,000 users
